# Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Source: https://onco.cc/trials/nct06008106/  
OnCo record `nct06008106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in melanoma, now recruiting.

## Summary

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma is a phase 3 interventional study registered as NCT06008106 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-11-02. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06008106
- Phase: 3
- Setting: Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy
- Sponsor: Shanghai Kechow Pharma, Inc.
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT06008106: https://clinicaltrials.gov/study/NCT06008106

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Tunlametinib](https://onco.cc/drugs/tunlametinib/)
- companies: [Shanghai Kechow Pharma](https://onco.cc/companies/shanghai-kechow-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06008106.json